Skip to main content

Hematologic Malignancy clinical trials at UC Davis

6 research studies open to eligible people

Showing trials for
  • A Study of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

    open to eligible people ages 18 years and up

    The purpose of this study is to determine the overall response rate of patients with Multiple Myeloma to the combination of Daratumumab, Ixazomib, Pomalidomide and Dexamethasone.

    La Jolla, California

  • A Study of Engineered Donor Grafts (TregGraft) for Allogeneic Transplantation for Hematologic Malignancies (blood cancer)

    open to eligible people ages 18-75

    This study will evaluate the safety, tolerability, and efficacy of an engineered donor graft ("Orca-T", a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells) in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic malignancies.

    Sacramento, California and other locations

  • A Study of KPG-818 in Hematological Malignancies (Blood & Immune System Cancers)

    open to eligible people ages 18 years and up

    This is a Phase 1, multicenter, open-label, multiple-ascending dose study to evaluate the safety, PK, and preliminary clinical activity of KPG-818 in combination with dexamethasone in adult subjects with multiple myeloma (MM), and KPG-818 as monotherapy in subjects with other selected hematological malignancies, including mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), adult T-cell leukemia lymphoma (ATL), indolent lymphoma, such as follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), etc. This study will assist in identifying appropriate, well tolerated doses that can be administered in subsequent studies in subjects with selected hematological malignancies.

    Sacramento, California and other locations

  • A Study of Oral LY3410738 in Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

    open to eligible people ages 18 years and up

    This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent IDH inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who may have received standard therapy

    Sacramento, California and other locations

  • Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

    “Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”

    open to eligible people ages 18 years and up

    This phase II trial evaluates the effect of azacitidine or decitabine and venetoclax in treating patients with acute myeloid leukemia that has not been treated before (treatment naive) or has come back (relapsed). Chemotherapy drugs, such as azacitidine, decitabine, and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

    Sacramento, California and other locations

  • A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

    “Assessing new blood cells growth after transplant using cord blood units that do not meet FDA guidelines but meet NMDP guidelines”

    open to all eligible people

    This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.

    Sacramento, California and other locations

Last updated: